Scotiabank keeps Sector Outperform on Pfizer, sets $33 target
Scotiabank reiterated a Sector Outperform rating on Pfizer and maintained a $33.00 price target, implying 20.0% upside versus Pfizer’s Oct 6 close of $27.50.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.